Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06802042

Effect of Lactobacillus DSM17938+ on Functional Constipation and Intestinal Flora in Pregnant Women

Constipation (constipation) is a common clinical symptom, including difficulty in defecation and / or reduced frequency of defecation, dry and hard stool, difficulty in defecation, feeling of inexhaustible defecation, feeling of anorectal obstruction, time-consuming defecation and need for auxiliary defecation. Reduced defecation means defecation less than 3 times a week.Constipation is very common during pregnancy, and studies have found that the incidence of constipation in pregnant women is as high as 40%. Among them, the prevalence of functional constipation in the early, middle, late and postpartum pregnancies is 35%, 39%, 21% and 17% respectively, with the highest in the early and middle pregnancies.Constipation can increase the psychological burden of pregnant women and affect their quality of life. Long-term severe constipation can also induce or aggravate hemorrhoids. Severe constipation can induce uterine contractions, which will adversely affect the pregnancy outcome of pregnant women.Studies have found that there is a difference in the abundance of intestinal flora between patients with constipation during pregnancy and pregnant women without digestive tract diseases.Although microecological preparations are not front-line drugs for the treatment of chronic constipation, they can promote intestinal peristalsis and the recovery of gastrointestinal motility by regulating the imbalance of intestinal flora. More and more researchers recommend them as long-term adjuvant drugs for chronic constipation. Probiotics are a type of microecological preparation, which refers to living microorganisms that can have beneficial health effects on the host after ingesting a sufficient amount.It is relatively safe to supplement probiotics during pregnancy.Our research team found a probiotic strain, Lactobacillus reuteri DSM17938+, which has no significant difference in improving constipation symptoms in patients with constipation compared with lactulose, and is even more effective than lactulose in alleviating abdominal pain and flatulence symptoms.However, clinical studies proving that Lactobacillus reuteri DSM17938 + is effective on constipation are generally concentrated abroad, and mainly focus on infants and young children, children, adults] or intestinal colic. Data on maternal population in China is lacking.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Chinese Academy of Medical Science & Peking Union Medical College Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (1) Pregnant women, age ≥18 years and <40 years old, and gestational age <28 weeks; (2) Must meet two or more of the following symptoms (Refer to the Roman IV standard):
  • It is difficult to defecate at least 25% of the time;
  • It is lumpy or hard stool at least 25% of the time;
  • It is not enough to defecate at least 25% of the time;
  • It is at least 25% of the time that there is anorectal obstruction or obstruction in defecation;
  • It requires manual assistance at least 25% of the time;

⑥It is spontaneous defecation less than 3 times a week. At the same time, loose stools rarely occur when no laxatives are used, which does not meet the diagnostic criteria of irritable bowel syndrome (IBS). The symptoms in the past 2 weeks have met the above diagnostic criteria.

(3) Pregnant women receive and follow high-protein and high-fiber dietary guidance during the first trimester.

(4) There were no other complications. (5) No medication was used to interfere with constipation symptoms.

Exclusion criteria

  • (1) Non-pregnant women, age <18 years or ≥40 years old, and gestational age ≥28 weeks; (2) Constipation caused by intestinal and systemic organic factors, drugs and other reasons, or concurrent with other non-constipation intestinal diseases; (3) History of use of antibiotics, probiotics, prebiotics, etc. in the past 2 weeks; (4) Pregnant women with thyroid disease, diabetes, hypertension, obesity, overweight or any metabolic disease.

Treatment and study plan

Intervention with probiotic bacteria

Other

The intervention group (n=20) received free intervention with probiotic bacteria (Lactobacillus reuteri DSM 8 +) for 4 weeks (1 bag bid)

Lactulose oral solution treatment

Drug

The control group (n=20) received lactulose oral solution free of charge for 4 weeks (1-2 bags qd for the first three days, and then increased or reduced according to constipation)

Primary outcomes

  1. Efficacy of probiotic bacteria (Lactobacillus reuteri DSM17938+) on functional constipation in pregnant women during the first and second trimester

    Time frame: From enrollment to the end of treatment at 4 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Peking Union Medical College Hospital

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Jan 30, 2025
Registry last updated
Jan 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.